Novo Nordisk is beefing up its hematologic portfolio with the $1.1 billion acquisition of Forma Therapeutics, snagging the company’s late-stage sickle cell anemia candidate etavopivat.
Source: Drug Industry Daily
Novo Nordisk is beefing up its hematologic portfolio with the $1.1 billion acquisition of Forma Therapeutics, snagging the company’s late-stage sickle cell anemia candidate etavopivat.
Source: Drug Industry Daily